LaSara Medical Group review

LaSara is unusually specific about what it sells. Sermorelin is sold as a 10 mL vial at 2,000 mcg/mL, the NAD⁺ vial is described as 200 mg/ml in a 10 ml presentation with two stated dose levels, testosterone is $169 a month with routine lab work stated as included, and Dr. Sunil Kurup is named as medical director and supervising physician. Publishing strength and volume alongside a price is what makes a comparison possible at all. The weak spots are paperwork and consistency: no legal entity and no named compounding pharmacy, a national claim with no state list behind it, and peptide pages whose plan lengths and sticky price bar do not agree with each other.

LaSara Medical Group is a national telehealth practice with in-person availability in Southern California, running a multi-modality menu rather than a single-drug platform: compounded semaglutide and tirzepatide for weight, a "reverse aging" line with NAD⁺ injections, sermorelin (injectable and nasal spray), glutathione and B12, a testosterone line in injectable, topical, oral and needle-free forms, and enclomiphene as an alternative testosterone route. Intake begins with a free consultation and a medical form, and prescribing follows physician approval. Subscription orders are described as including delivery, physician monitoring and proactive check-ins.

Hybrid: national telehealth with the option of being seen in person in Southern California, under a named medical director and supervising physician. Product pages are structured as a storefront — you can see the subscription price and the one-time price side by side before starting anything — and the testosterone line is gated behind real requirements rather than a questionnaire alone: total testosterone, free testosterone, a complete blood count and a total PSA no more than six months old, or new testing through LaSara. That gate is the correct standard for testosterone and a good sign about how the practice runs. The gaps are on paperwork. No legal entity or state of incorporation is disclosed; the linked terms page is generic Practice Web Site text with PatientPop template language, and the compounding pharmacy is not named — product copy refers only to "our Legitscript Certified pharmacies". LaSara displays a LegitScript seal of its own on product pages, which is a claim about the practice's site rather than its suppliers. No per-state availability list is published despite the national telehealth positioning, and its peptide pages carry benefit copy without a compounded-medication disclaimer alongside, which is a disclosure the practice should tighten.

Sermorelin is $242 for six weeks, $449 for twelve and $719 for eighteen on subscription; one-time six- and twelve-week options are $269 and $499. A sticky bar still labels $288 as monthly, while the plan selector uses multiweek periods. NAD⁺ injection is $248 on subscription for one high-dose month or two moderate-dose months, with one-time options from $150; its sticky bar shows $225 monthly. Neither multiweek product supports a simple monthly floor. TRT remains $169/month with medication, supplies, follow-up consults, routine labs and shipping stated as included; new labs cost $69 if needed. Product pages allow pause or cancellation, but the generic linked terms do not establish a prescription-specific refund or first-debit rule. Confirm the selected supply and charge.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. LaSara does not name the pharmacy that prepares its compounded products, and compounded sterile preparations are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence the menu splits three ways. Sermorelin is a GHRH analog acting on your own pituitary — a real mechanism, thin long-term human outcome data. Injected NAD⁺ has no controlled human outcome trials whatever the concentration on the vial; the forms with human data are the oral precursors NR and NMN, which raise blood NAD⁺, a biomarker rather than an outcome. Testosterone replacement is the outlier with a genuine randomized evidence base, including a large cardiovascular safety trial, but it also carries real monitoring obligations — hematocrit, PSA and testosterone levels — and suppresses natural production and fertility, which is precisely why LaSara's lab gate exists. Enclomiphene is the opposite trade: it raises endogenous testosterone by blocking estrogen feedback at the pituitary and preserves fertility, but it is not FDA-approved for that use and is prescribed compounded. Individual results vary.